Applied Research Systems Ars Holding N.v.

Merck Serono S. A.

Merck Patent Gmbh

Laboratoires Serono S.a.

Sean D McKenna

Mark Tepper

Stephen S Palmer

Aliza Eshkol

Michael C MacNamee

Mark J Cartwright

Olivier Leger

Xuliang Jiang

Horacio Gabriel Nastri

Christel Iffland

Qi An

Stephen Arkinstall

Robert K Campbell

Marco Muda

Mark Hilary Cunningham

Gian Luca Araldi

William Harold Brondyk

Zhong Zhao

Adulla P Reddy

Christie Ann Kelton

David I Sherris

Rene Lynn Schweickhardt

Gang Hao

Bagna Bao

Giampiero De Luca

Nabil El Tayar

Vanita D Sood

Chaomei He

Louise M Garone

Meijia Yang

Stephen J Arkinstall

The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.

Anti-PD-L1 antibodies and uses thereof

FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.

FSH glycosylation variant D3N

This disclosure relates to hybrid antigen binding molecules including at least two polypeptide chains, with at least one polypeptide chain comprises an antigen binding moiety linked to an amino acid sequence of a subunit of a heterodimeric proteinaceous hormone. Also disclosed are methods of making and using such hybrid antigen binding molecules for diagnosis and/or therapy.

Compositions and methods of producing hybrid antigen binding molecules and uses thereof

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

Methods of inducing ovulation

FSH mutants with increased glycosylation and longer half-lives are described. The use of FSH mutants for inducing folliculogenesis in human patients is also described.

FSH mutants

A novel FSH mutant with increased glycosylation and longer half-lifes for use in inducing folliculogenesis in human patients is described. The FSH mutant permits the use of lower cumulative doses of FSH to achieve the same or better clinical result.

FSH beta mutants that are glycosilated at residues N55 and T57

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

Methods of inducing ovulation using a non-polypeptide camp level modulator

1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.

Gamma lactams as prostaglandin agonists and use thereof

The present invention is directed to methods of increasing oocyte production in a mammal. More specifically, the specification describes methods and compositions for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.

Inhibitors of phosphodiesterases in infertility

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase type 4.

Growing community of inventors

Duxbury, MA, United States of America

Sean D McKenna